In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae247 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Nicolas Bourgon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Fetal Medicine Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Valganciclovir, Cytomegalovirus Infections, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
The treatment of congenital cytomegalovirus (CMV) infection is usually administered to neonates after birth; however, it can be anticipated during the prenatal period by treating pregnant women in order to reduce the severity of the congenital disease. The most commonly used treatment for CMV during pregnancy is valaciclovir; however, valganciclovir has a higher potency against CMV and is the first choice for neonates with congenital CMV disease.
Objectives
We investigated neonatal and maternal safety of tertiary prevention in infected fetuses showing ultrasound features of infection using valganciclovir.
Methods
Retrospective cohort study of pregnant women and their symptomatic infected fetuses taking valganciclovir, 3 × 450 mg per day. All fetuses presented at least one prenatal feature on ultrasound. We assessed fetal/neonatal and maternal safety, as well as neonatal efficacy of treatment. The main outcome was neutropenia. Secondary outcomes included other haematological side effects, symptoms at birth and neonatal CMV-PCR was positive.
Results
Seventeen women with singleton pregnancies received valganciclovir from a median (IQR) of 27.1 (26.0–30.3) to 11.6 (6.5–12.9) weeks of gestation. No neonatal neutropenia was reported. One pregnancy was terminated for severe features. Three newborns (18%) were asymptomatic at birth, including one with negative CMV-PCR from blood and saliva. CMV-PCR was positive for 12/13 symptomatic newborns, with a median (IQR) log10 viral load of 3.36 (3.30–4.20), 4.03 (1.75–4.27) and 3.04 (0.00–3.40) log10 copies/mL in blood, urine and saliva, respectively.
Conclusions
Tertiary prevention by valganciclovir appears to be well tolerated for both fetus and mother. However, more extensive trials accompanied by long-term follow-up are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Obstetrics and Fetal Medicine Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.
- INSERM UMR-1163, Institut Imagine, Université Paris Cité, Paris, France.
- Virology Laboratory-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.
- URP « FŒTUS » 73-28, Université Paris Cité, Paris, France.
- Neonatal Medicine and Intensive Care Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.
ORCID-Profile: Nicolas Bourgon, Jacques Fourgeaud
Zitieren
APA
Bourgon, N., Lopez, R., Fourgeaud, J., Guilleminot, T., Bussières, L., Magny, J. F., Ville, Y., & Leruez Ville, M. (2024). In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae247
Vancouver
Bourgon N, Lopez R, Fourgeaud J, Guilleminot T, Bussières L, Magny JF, et al. In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae247
BibTeX
@article{Bourgon2024,
author = {Bourgon, Nicolas and Lopez, Remi and Fourgeaud, Jacques and Guilleminot, Tiffany and Bussières, Laurence and Magny, Jean-François and Ville, Yves and Leruez Ville, Marianne},
title = {In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae247}
}
EUVIMED